HUTCHMED Completes Enrollment of Phase III Trial

Summary by AI BETAClose X

Hutchmed (China) Limited announced the completion of patient enrollment for the SANOVO Phase III trial on August 18, 2025. This trial investigates the combination of ORPATHYS® (savolitinib) and TAGRISSO® (osimertinib) as a first-line treatment for certain non-small cell lung cancer (NSCLC) patients with EGFR mutation and MET overexpression in China. Topline results are expected in the second half of 2026, potentially leading to a supplementary New Drug Application submission to China's NMPA. The study is a blinded, randomized, controlled trial evaluating efficacy and safety, with the primary endpoint being progression-free survival (PFS) assessed by investigators. Other endpoints include PFS (independent review committee assessment), overall survival (OS), objective response rate (ORR), duration of response (DoR), disease control rate (DCR), time to response (TTR), and safety. The trial's identifier is NCT05009836.

Disclaimer*

UK 100

Latest directors dealings